Explore

Trendline Trendline
Formosa Pharmaceuticals to Present TSY-310 at ASCO 2026, Highlighting Antitumor Efficacy

Formosa Pharmaceuticals to Present TSY-310 at ASCO 2026, Highlighting Antitumor Efficacy

Formosa Pharmaceuticals to Present TSY-310 at ASCO 2026, Highlighting Antitumor Efficacy
Trendline Trendline
SystImmune to Present New Clinical Data on Izalontamab Brengitecan at ASCO 2026

SystImmune to Present New Clinical Data on Izalontamab Brengitecan at ASCO 2026

SystImmune to Present New Clinical Data on Izalontamab Brengitecan at ASCO 2026
Trendline Trendline
Bristol Myers Squibb to Showcase Oncology Innovations at ASCO 2026

Bristol Myers Squibb to Showcase Oncology Innovations at ASCO 2026

Bristol Myers Squibb to Showcase Oncology Innovations at ASCO 2026
Trendline Trendline
Accent Therapeutics to Present Clinical Study on ATX-295 at ASCO Meeting, Targeting Chromosomal Instability in Cancer

Accent Therapeutics to Present Clinical Study on ATX-295 at ASCO Meeting, Targeting Chromosomal Instability in Cancer

Accent Therapeutics to Present Clinical Study on ATX-295 at ASCO Meeting, Targeting Chromosomal Instability in Cancer
Trendline Trendline
858 Therapeutics Reports Promising Results from Phase 1/2 Trial of PARG Inhibitor ETX-19477 in Cancer Treatment

858 Therapeutics Reports Promising Results from Phase 1/2 Trial of PARG Inhibitor ETX-19477 in Cancer Treatment

858 Therapeutics Reports Promising Results from Phase 1/2 Trial of PARG Inhibitor ETX-19477 in Cancer Treatment
Trendline Trendline
Formosa Pharmaceuticals to Present TSY-310 at ASCO Annual Meeting, Highlighting Antitumor Efficacy

Formosa Pharmaceuticals to Present TSY-310 at ASCO Annual Meeting, Highlighting Antitumor Efficacy

Formosa Pharmaceuticals to Present TSY-310 at ASCO Annual Meeting, Highlighting Antitumor Efficacy
Trendline Trendline
Bristol Myers Squibb to Present New Oncology Data at ASCO 2026 Highlighting Innovative Cancer Treatments

Bristol Myers Squibb to Present New Oncology Data at ASCO 2026 Highlighting Innovative Cancer Treatments

Bristol Myers Squibb to Present New Oncology Data at ASCO 2026 Highlighting Innovative Cancer Treatments
Trendline Trendline
Accent Therapeutics to Present Phase 1/2 Study of ATX-295 at ASCO 2026

Accent Therapeutics to Present Phase 1/2 Study of ATX-295 at ASCO 2026

Accent Therapeutics to Present Phase 1/2 Study of ATX-295 at ASCO 2026
Trendline Trendline
Corbus Pharmaceuticals Appoints Nishant Saxena as Chief Business Officer Amidst Key Clinical Developments

Corbus Pharmaceuticals Appoints Nishant Saxena as Chief Business Officer Amidst Key Clinical Developments

Corbus Pharmaceuticals Appoints Nishant Saxena as Chief Business Officer Amidst Key Clinical Developments
Trendline Trendline
SAGA Diagnostics Unveils Data on Pathlight MRD Test at ASCO 2026, Highlighting Cancer Treatment Advancements

SAGA Diagnostics Unveils Data on Pathlight MRD Test at ASCO 2026, Highlighting Cancer Treatment Advancements

SAGA Diagnostics Unveils Data on Pathlight MRD Test at ASCO 2026, Highlighting Cancer Treatment Advancements
Trendline Trendline
Eisai Presents New Clinical Evidence for Lenvatinib at ASCO 2026

Eisai Presents New Clinical Evidence for Lenvatinib at ASCO 2026

Eisai Presents New Clinical Evidence for Lenvatinib at ASCO 2026
Trendline Trendline
FDA Accepts ImmunityBio's Supplemental BLA for ANKTIVA Plus BCG in Bladder Cancer Treatment

FDA Accepts ImmunityBio's Supplemental BLA for ANKTIVA Plus BCG in Bladder Cancer Treatment

FDA Accepts ImmunityBio's Supplemental BLA for ANKTIVA Plus BCG in Bladder Cancer Treatment